Viatris is like **Teva Pharmaceuticals, but with a substantial portfolio of popular, off-patent brand-name drugs** (such as Lipitor and Viagra) in addition to its extensive range of generics and biosimilars, distributed globally.

Alternatively, think of Viatris as the **Procter & Gamble of established prescription medicines**, manufacturing and globally distributing a vast array of familiar generic, biosimilar, and brand-name drugs whose patents have expired.

• Brand Drugs: A diverse portfolio of prescription medications, including well-known names such as Lyrica, Lipitor, Creon, Influvac, EpiPen, Norvasc, Viagra, and Celebrex.
• Generic and Complex Generic Drugs: A broad offering of chemically identical or highly similar versions of branded prescription drugs, including those with complex formulations.
• Biosimilars: Biologic medicines that are highly similar to an already approved reference biologic, featuring franchises like Fulphila, Ogivri, Hulio, and SEMGLEE.
• Active Pharmaceutical Ingredients (APIs): Core chemical components used in the manufacture of various pharmaceutical products across numerous therapeutic categories.
• Patient Support Services: Services designed to assist patients in managing their health, encompassing diagnostic clinics, educational seminars, and digital tools.

Viatris Inc. (VTRS) primarily sells its pharmaceutical products and active pharmaceutical ingredients (APIs) to other companies and organizations within the healthcare supply chain, rather than directly to individual consumers. The company's business model involves distributing its products through various channels to reach end-users.

Based on the company description, Viatris's major customer categories and prominent public companies within those categories include:

• Pharmaceutical Wholesalers and Distributors: These companies are critical intermediaries that purchase large volumes of pharmaceutical products from manufacturers like Viatris and then distribute them to pharmacies, hospitals, and other healthcare providers across various markets.
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)
• Pharmaceutical Retailers and Pharmacy Benefit Managers (PBMs): This category includes major pharmacy chains, mail-order pharmacies, e-commerce pharmacies, and companies that manage prescription drug benefits for large health plans. These entities are significant direct or indirect purchasers of medicines.
  • CVS Health Corporation (CVS) (operates CVS Pharmacy and is a major PBM through CVS Caremark)
  • Walgreens Boots Alliance, Inc. (WBA) (operates Walgreens pharmacies)
  • Cigna Corporation (CI) (parent company of Express Scripts, a major PBM)
  • UnitedHealth Group (UNH) (parent company of OptumRx, another major PBM, and a large health insurer)
• Healthcare Payers and Insurers: Large health insurance companies and other payers often negotiate directly with pharmaceutical manufacturers or distributors to procure medications for their covered members. Governments also fall into this category through their health programs and procurement efforts.
  • UnitedHealth Group (UNH)
  • Elevance Health, Inc. (ELV)
  • Cigna Corporation (CI)
  • Humana Inc. (HUM)
• Healthcare Institutions: This broad category encompasses hospitals, clinics, and other healthcare facilities that purchase medications for use within their establishments. These purchases may be direct or through group purchasing organizations.

• Biocon Ltd. (BIOCON.NS)
• Revance Therapeutics, Inc. (RVNC)
• Theravance Biopharma, Inc. (TBPH)
• Fujifilm Kyowa Kirin Biologics Co. Ltd.

Scott A. Smith, Chief Executive Officer

Scott A. Smith is the Chief Executive Officer of Viatris and a member of the company's board of directors. He has over 35 years of experience in the global biotechnology and pharmaceutical sectors. Prior to becoming CEO of Viatris in April 2023, Smith served as President of BioAtla, Inc., a global biotechnology company focused on developing antibody therapeutics. Before that, he was President and Chief Operating Officer of Celgene Corporation, where he was instrumental in building and overseeing the clinical development, registration, launch, and global commercial success of the blockbuster drug Otezla®. He has also served on the boards of multiple public and private companies, including BioAtla, Apexigen, Titan Pharmaceuticals, Triumvira Immunologics, Refuge Biotechnologies, and F-star Therapeutics.

Theodora "Doretta" Mistras, Chief Financial Officer

Theodora "Doretta" Mistras assumed the role of Chief Financial Officer of Viatris in March 2024. She is an accomplished financial executive with extensive healthcare industry knowledge and nearly two decades of leadership, advisory, and capital markets experience. Before joining Viatris, Mistras served as Managing Director, Healthcare Investment Banking at Citigroup Global Markets, and previously held the same role at Goldman Sachs. Throughout her career, she has advised on transactions totaling over $240 billion in aggregate value, guiding corporate boards and executive teams on various strategic financial matters including mergers and acquisitions, joint ventures, and capital markets transactions.

Corinne Le Goff, Chief Commercial Officer

Corinne Le Goff joined Viatris as Chief Commercial Officer in April 2024. She brings over 25 years of experience in the biotechnology and pharmaceutical industries, leading and building successful global teams. Her previous roles include President and Chief Executive Officer of Imunon, a clinical-stage biotechnology company, where she spearheaded an organizational turnaround. She also served as Chief Commercial Officer at Moderna, responsible for establishing the commercial organization and capabilities for the global rollout of its COVID-19 vaccine. Le Goff spent six years at Amgen, where she held significant positions such as President of the U.S. Business, Senior Vice President of Global Product Strategy & Commercial Innovation, and President of the Europe Region. Early in her career, she held leadership positions at Roche, Merck, Sanofi, and Pfizer.

Matthew J. Maletta, Chief Legal Officer

Matthew J. Maletta was appointed Chief Legal Officer of Viatris, effective February 9, 2026. He possesses nearly 30 years of legal experience, leading legal teams for both generic and branded pharmaceutical companies. From 2015 to 2025, Maletta served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Endo, where he oversaw the company's merger with Mallinckrodt and the subsequent spin-off of Par Health. Before his tenure at Endo, he spent over a decade at Allergan, rising to Vice President, Associate General Counsel, and Corporate Secretary. At Allergan, he was the lead attorney for business development transactions, including the $70 billion sale of Allergan to Actavis.

Andrew Enrietti, Chief Administrative and Transformation Officer

Andrew Enrietti serves as Viatris' Chief Administrative and Transformation Officer. No detailed background information on prior companies founded, managed, or private equity involvement was available in the provided search results.

Here are the key risks to Viatris's business:

1. Competitive Pressure and Price Erosion in the Generic Drug Market: Viatris operates in a highly competitive global generic drug market, which leads to significant price erosion and pressure on profit margins. The entry of numerous competitors, including companies like Teva Pharmaceutical Industries Ltd. and Sandoz Group AG, contributes to a "race to the bottom" on price for many traditional generic products. This competitive landscape, exacerbated by factors such as the Inflation Reduction Act (IRA) in the U.S., consistently impacts Viatris's revenue and market share.
2. Regulatory Hurdles and Manufacturing Challenges: A significant risk for Viatris stems from regulatory scrutiny and operational issues at its manufacturing facilities. Notably, an FDA warning letter and import alert concerning its oral finished dose manufacturing facility in Indore, India, has caused substantial supply disruptions and negatively impacted total revenues and adjusted EBITDA. Such regulatory actions can restrict product distribution, lead to increased costs for compliance and remediation, and significantly affect financial performance.
3. High Debt Load and Financial Leverage: Viatris carries a substantial debt load, which, despite active efforts to reduce it, remains a significant financial risk. As of September 2025, the company had approximately $14.7 billion in total debt. High leverage can limit the company's financial flexibility, increase its susceptibility to industry-wide challenges like generic drug pricing pressures and foreign exchange volatility, and can lead to non-cash goodwill impairment charges, impacting GAAP net earnings.

Viatris Inc. (VTRS) operates in various therapeutic areas and offers a wide range of products, including prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. The addressable markets for some of their main products and services are detailed below:

• Lyrica (Pregabalin): The global pregabalin market size was valued at approximately USD 1.8 billion in 2024 and is projected to grow to USD 3 billion by 2034. In the U.S. alone, this market was valued at USD 754 million in 2024. Other estimates place the global market for pregabalin at about USD 4.2 billion in 2022, with the United States contributing nearly 55% of sales, approximately USD 2.3 billion.
• Lipitor (Atorvastatin): The global atorvastatin market size was USD 4,624.2 million in 2024. North America accounted for a significant portion, with a market size of USD 1,849.68 million in 2024. The global market is projected to reach USD 6,003.69 million by 2031.
• EpiPen auto-injector (Epinephrine autoinjector): The global epinephrine autoinjector market size was estimated at USD 2,158.2 million in 2024. North America held a substantial share, with a market size of USD 863.28 million in the same year. The market is expected to reach USD 3698.7 million by 2031. Another source indicates the global market reached USD 2.6 billion in 2024 and is expected to grow to USD 5.3 billion by 2033.
• Creon (Pancrelipase): The global pancrelipase market size was estimated at USD 1.064 billion in 2024 and is projected to increase to USD 1.81 billion by 2035. North America is the largest market for pancrelipase, accounting for approximately 45% of the global share. Another report values the global market at approximately USD 1.8 billion in 2023, with projections to reach around USD 3.1 billion by 2032.
• Celebrex (Celecoxib): As of 2023, the global market for celecoxib was valued at approximately USD 2.3 billion. The North American market represents roughly 50% of these sales. The global celecoxib market size is expected to reach USD 3393.52 million by 2033.
• Fulphila (Pegfilgrastim Biosimilar): The global pegfilgrastim biosimilar market is estimated to be valued at USD 4.5 billion in 2025 and is projected to reach USD 9.3 billion by 2035. North America is a key region in this market.
• Ogivri (Trastuzumab Biosimilar): The global trastuzumab biosimilars market size is expected to grow from USD 6.9 billion in 2025 to USD 8.86 billion in 2026, with projections to reach USD 24.48 billion by 2030. North America was the largest region in this market in 2025.
• Hulio (Adalimumab Biosimilar): The global adalimumab biosimilar market size was valued at USD 897.85 million in 2025 and is expected to reach USD 8.1 billion by 2035.
• Biosimilars (General): The overall global biosimilars market size was estimated at USD 39.59 billion in 2025 and is projected to reach USD 151.58 billion by 2033. North America held the largest revenue share in the biosimilars market in 2025, accounting for 42.56% of the global revenue.

For Viatris (VTRS), several key drivers are expected to fuel future revenue growth over the next 2-3 years:

1. New Product Launches and Pipeline Advancements: Viatris anticipates significant contributions from new product revenues, projecting between $450 million and $550 million in 2026. The company's pipeline includes upcoming launches for 2026-2027, such as fast-acting meloxicam, cenerimod, and selatogrel, which are expected to support mid-single-digit sales growth and improve margins. Recent regulatory milestones, including FDA approvals for generic injectable medications and the acceptance of new drug applications for a low-dose estrogen weekly contraceptive patch, further underscore the potential for new product streams. Furthermore, Viatris is strategically focusing on complex generics and biosimilars, aiming to capitalize on the "biosimilar boom" as high-cost biologic drugs lose patent protection.
2. Strategic Geographic Expansion and Performance: The company expects continued operational revenue growth across key regions, particularly Europe, Greater China, and Emerging Markets. Specifically, Europe is projected to grow 4% year-over-year in 2026, while Emerging Markets and Greater China are expected to see growth of 6% and 3%, respectively. This regional focus leverages Viatris's established global presence to drive revenue.
3. Realization of Cost Savings and Reinvestment into Growth Initiatives: Viatris has undertaken an enterprise-wide strategic review targeting approximately $650 million in gross cost savings by the end of 2028. A significant portion of these savings (approximately $250 million) is planned for reinvestment into growth initiatives, particularly in higher-value brands and research and development, which is anticipated to enhance future revenue generation and improve margins.
4. Focus on Higher-Value Specialty and Biosimilar Products: A strategic pivot towards higher-value specialty medicines and biosimilars is a crucial growth driver. Viatris is investing in new specialty pillars such as ophthalmology and gastroenterology, with an ambitious goal to achieve over $1 billion in annual ophthalmology sales by 2028. The company's ability to navigate complex regulatory pathways for technically challenging products, such as its first approved injectable using microsphere technology, reinforces this shift towards a more profitable product mix. The temporary increase in Medicare Part B reimbursement for biosimilars through 2027 also acts as a tailwind for this segment.

Share Repurchases

• Viatris returned over $1 billion to shareholders through dividends and share repurchases in 2025.
• As of the third quarter of 2025, Viatris had returned more than $920 million to shareholders, including $500 million in share repurchases, and anticipated completing between $500 million and $650 million in total share repurchases for the full year 2025.
• The company has a share repurchase program authorizing the repurchase of up to $2.0 billion of its common stock.

Outbound Investments

• In October 2025, Viatris acquired Aculys Pharma, gaining rights to Pitolisant in Japan and Spydia® in Japan and certain other markets in the Asia-Pacific region.
• Viatris announced in late 2022 and completed in Q1 2023 the acquisition of Oyster Point Pharma and Famy Life Sciences for an aggregate purchase price of approximately $700-$750 million, establishing a new ophthalmology franchise.
• In 2024, Viatris expanded its portfolio by acquiring rights to three new products (Cenerimod, Selatogrel, and Sotagliflozin) from Idorsia for an upfront payment of $350 million, along with potential milestones and royalties.

Capital Expenditures

• Capital expenditures for Viatris amounted to $379 million in 2025.
• The company's estimated capital expenditures for 2021 were projected to be between $0.5 billion and $0.65 billion.
• Viatris focuses its capital expenditures on expanding its product pipeline and investing in advanced manufacturing technologies.